Kornimate/medical-research-clean huggingface dataset:
frequency of circulating tumor cells (ctcs) and amount of cell-free dna (cfdna) in cirrhotic patients with hepatocellular carcinoma (hcc)

Conditions: Hepatocellular Carcinoma

Summary: all consecutive patients with liver cirrhosis, with clinical and imaging features suggestive of hepatocellular carcinoma (hcc) attending the department of hepatology, institute of liver and biliary sciences (ilbs) from february 2017 to december 2018 will be evaluated for inclusion.based on the previous years data of hcc patients admitted to ilbs. cirrhotic patients aged 18-70 years, with hcc proven by typical radiological features of arterial enhancement and delayed wash-out, on one or both of dynamic computerized tomographic or dynamic magnetic resonance imaging (mri), as per updated american association for the study of liver disease (aasld) guidelines (details in appendix1). age and gender matched patients with cirrhosis, but without hcc, seen during the same study period will serve as controls. patient characteristics, etiology of cirrhosis, and liver function parameters will be noted. investigator will stage the included patients as per the barcelona cancer of liver cancer (bclc) criteria (details in appendix1). investigator will then estimate circulating tumor cells (ctc) and cfdna in peripheral blood samples of the patients and controls.


Eligibility criteria:
inclusion criteria: * age between 18-70 years. * proven cirrhosis (defined in appendix 1). * hcc proven by standard radiological criteria within last 1-month (for cases) * no hcc on dynamic ct and/or dynamic mri (protocol defined in appendix 1) done within last 1 month (for control group). exclusion criteria: * previous biopsy or fna of the tumor. * previous invasive radiological procedures tace/rfa. * previous or ongoing chemotherapy or biological therapy. * previous liver resection or transplant. * segmental / main pv thrombosis. * atypical enhancement on imaging * extrahepatic metastatic spread of hcc * \>70 years of age * coexisting sepsis. * renal dysfunction, as defined by serum creatinine \>1.5mg/dl.
vasopressor outcomes in spine surgery

Conditions: Hypotension

Summary: this is a prospective, randomized control trial comparing norepinephrine versus phenylephrine for vasopressor support in patients undergoing elective spinal fusion surgery.

there is limited evidence on the difference in postoperative outcomes between the choices of vasopressors used to treat intraoperative hypotension (ioh) in patients undergoing non-cardiac surgery under general anesthesia. a recent pilot feasibility trial comparing norepinephrine and phenylephrine for first-line intravenous infusion of vasopressor during general anesthesia and major non-cardiac surgery was unable to show any difference in postoperative outcomes. although the study demonstrated safety and feasibility, it was not powered to detect differences in postoperative outcomes. the impact of vasopressors on postoperative outcomes in patients undergoing complex spinal surgery in the prone position is even scarcer. while it has been demonstrated that the use of intra-operative vasopressor infusion is safe and well tolerated, without any adverse renal outcomes, it is unclear if the choice of vasopressor makes any difference. while animal studies have shown that norepinephrine may provide greater spinal cord protection than phenylephrine, clinical studies in humans are lacking. we aim to fill this gap in knowledge by carrying out a prospective, randomized control trial to evaluate differential outcomes related to the choice of norepinephrine versus phenylephrine as the preferential vasopressor in patients undergoing elective spinal fusion surgery in the prone position.

Eligibility criteria:
inclusion criteria: -patients \> 18 years undergoing elective, prone, spinal fusion surgery exclusion criteria: * age \< 18 years * emergency surgery * outpatient surgery * pregnancy * end-stage renal disease requiring dialysis * diagnosed myocardial ischemia and/or cardiac revascularization within the past month

Keywords: vasopressor phenylephrine norepinephrine spine surgery general anesthesia
ultrasound assessment of metoclopramide effect on gastric volume in cesarean section

Conditions: Aspiration Pneumonia

Summary: the risk of aspiration pneumonitis during cesarean sections has significantly decreased. nevertheless, precaution against gastric aspiration is still vital in patients in whom regional anesthesia contraindicated or in whom general anesthesia has to be administered (for example; during emergency cesarean delivery). the administration of intravenous anesthetics reduces the level of consciousness of a patient that compromises the protective reflexes of the upper airways. moreover, a high level of sedation also reduces the tone of the les (lower oesophageal sphincter). both these situations predispose the risk of aspiration pneumonia in patients awaiting surgical interventions in supine position under general anesthesia

since regional anesthesia has largely replaced general anesthesia, the risk of aspiration pneumonitis during cesarean sections has significantly decreased. nevertheless, precaution against gastric aspiration is still vital in patients in whom regional anesthesia contraindicated or in whom general anesthesia has to be administered (for example; during emergency cesarean delivery). the administration of intravenous anesthetics reduces the level of consciousness of a patient that compromises the protective reflexes of the upper airways. moreover, a high level of sedation also reduces the tone of the les (lower oesophageal sphincter). both these situations predispose the risk of aspiration pneumonia in patients awaiting surgical interventions in supine position under general anesthesia . the risk of aspiration increases in outpatients if the volume of the gastric contents increases beyond 25 ml, and its ph falls below 2.5. however, the risk of aspiration significantly decreases in "fasted" outpatients. since most patients awaiting elective surgery remains fasted, routine prophylaxis for preventing aspiration pneumonitis not recommended anymore. studies suggest that metoclopramide, in combination with h2-receptor antagonists (such as cimetidine), significantly reduces the risk of postoperative emesis and aspiration pneumonitis. however, the time available for administering oral prophylaxis with such anti-emetic and anti-histaminic is too short for these medications to be effective

Eligibility criteria:
inclusion criteria: * pregnant women * age range between 20 to 38 years * provided informed consent to participate. exclusion criteria: * patient refusal * associated co-morbidity as diabetes mllitus, hypertension, preeclampsia, renal or hepatic diseases * neurological and psychological disorders, , * chronic gastroesophageal reflux diseases
study to evaluate the safety and pharmacokinetics of inhaled ciprofloxacin in patients with mild to moderate chronic obstructive pulmonary disease (copd)

Conditions: Disease, Pulmonary

Summary: objectives of the study are to investigate the safety, tolerability and levels of ciprofloxacin in the lung after single and multiple inhalative administration to patients with mild to moderate copd (stage i-ii according to gold criteria).


Eligibility criteria:
inclusion criteria: * adult patients with copd (stage i or ii according to the gold classification), 35 years of age or older * airway obstruction with a post-bronchodilator forced expiratory volume (fev1) \> or equal 50% of predicted normal and a post-bronchodilator fev1 / forced vital capacity (fvc) \< 70%. * current or ex-smokers with a smoking history of more than 10 pack-years * body mass index (bmi) between 18 and 33 kg/m2 * written informed consent to participate in the study after receiving adequate previous information and prior to any study specific procedures exclusion criteria: * significant disease other than copd as bronchial asthma, cystic fibrosis or clinically evident bronchiectasis * total blood eosinophil count \>/=600/mm3. * thoracotomy with pulmonary resection * regular use of daytime oxygen therapy * completion of a pulmonary rehabilitation program in the six weeks prior to the pre-study examination or current participation in a rehabilitation program * hypersensitivity to the investigational drug or to other quinolones and/or to inactive constituents of the inhalation powder * hypersensitivity of the bronchial system to inhalation of nebulized drugs or saline solution * acute pulmonary exacerbation * patients with a history of severe allergies, non-allergic drug reactions, or multiple drug allergies * concomitant inhalative therapy with antibiotics and/or concomitant systemic therapy with fluoroquinolones * oral beta-adrenergics, beta blockers * long acting anti-cholinergics within 2 weeks prior to pre-study examination * inhaled or oral steroids * methylxanthines: 24-hour washout of short-acting theophylline and 48-hour washout of long-acting theophylline prior to pre-study examination * antihistamines, antileukotrienes prescribed for asthma * oral cromolyn sodium or oral nedocromil sodium

Keywords: ciprofloxacin inhalation pharmacokinetics safety tolerability copd
effects of different oxygen concentrations on pulmonary complications in patients undergoing radical resection of esophageal cancer

Conditions: Atelectasis, Postoperative

Summary: radical operation of esophageal cancer is complicated and traumatic, and ventilation with one lung in lateral position and ventilation with both lungs after supine position requires long-term tracheal intubation and ventilator-assisted ventilation, and the incidence of postoperative pulmonary complications is high.

therefore, we should explore the most appropriate lung protection ventilation strategy to reduce the occurrence of pulmonary complications. the recommended standard of international expert group on lung protective ventilation strategy points out that the lowest concentration of oxygen (≤40%) should be inhaled as much as possible during mechanical ventilation to maintain normal blood oxygen level (spo2≥94%). if the mixed gas with low inhaled oxygen concentration can achieve ideal oxygen saturation and arterial oxygen partial pressure, it may reduce the postoperative pulmonary complications of the subjects. however, there are few reports on the influence of different oxygen concentrations on pulmonary complications in patients undergoing radical resection of esophageal cancer. this study intends to explore the influence of different oxygen concentrations on pulmonary complications in patients undergoing radical resection of esophageal cancer.

Eligibility criteria:
inclusion criteria: * american association of anesthesiologists (asa) patients with i-ii physical condition; * patients with preoperative partial pressure of blood gas and oxygen greater than 80mmhg who were scheduled for elective esophageal cancer surgery were operated in the right lateral position first and then in the supine position. exclusion criteria: * there is a history of acute lung injury with acute respiratory distress syndrome within three months; * heart failure (classified by new york heart association) is greater than grade iv, * there is a serious liver and kidney dysfunction (children with grade b or c liver failure, glomerular filtration rate \< 30 ml/min); * body mass index \> 30kg/m2； * coagulation dysfunction; * operation time exceeds 10h * the amount of bleeding is more than 800ml, and the total fluid volume is more than 3000ml.
evaluation of physiological variables and detection of blood loss using the zynex fluid monitoring system, model cm-1600

Conditions: Fluid Loss

Summary: the study is a prospective, non-randomized, non-blinded, non-significant risk, multi-center study enrolling up to 500 healthy adult subjects consented to undergo a whole blood donation procedure. the study will involve enrolling subjects that will undergo blood donation wearing the study device (cm-1600 device) and capture study-required physiological parameters pre-, during, and post-donation.


Eligibility criteria:
inclusion criteria: * ability to provide written consent * ability and willingness to comply with the study procedures and duration requirements * 18 years of age or older * consented and eligible to undergo a single unit whole blood donation exclusion criteria: * females who are pregnant or breastfeeding * undergone an amputation of any upper extremity * diagnosed with dextrocardia * subjects who have a pacemaker * subjects with body hair density which prevents adequate application of device electrodes
endocrine changes and their correction in heart and lung transplant recipients and donors

Conditions: Endocrine System Diseases; Thyroid Diseases; Cortisol Deficiency; Diabetes Insipidus; End-stage Heart Failure; End Stage Lung Disease

Summary: the aim of this study is to assess the impact of endocrine changes and their correction on survival and organ function in heart and lung transplant recipients. this study also features an investigation of the hormone levels and hormonal replacement therapy of the donors to study its role in the function of the transplanted hearts and lungs. thyroid hormones (tsh, thyroxine, tri-iodothyronine), cortisol and the antidiuretic hormone will be studied. the former two hormone levels will be defined in the recipients just before transplantation and three days later. in the case of the donors all three hormones will be recorded at the time of the explantation. the investigators would like to record the hormonal replacement therapy in all our patients as well to see it's effect on survival and on the transplanted organ function. after the transplantation during the hospital stays all the important hemodynamic parameters, laboratory parameters, the result of the medical imagings, the medication, the length of icu and hospital stay and the complications were recorded. recipients will be followed for five years. organ function will be assessed every three month for a year, after than every six month for further four years. investigator would like to record the result of the cardiac echocardiography, spirometries, imaging, and complications. our purpose is to compare these results against the endocrine disorders and the replacement therapy.


Eligibility criteria:
inclusion criteria: * patients over 18 years of age admitted for heart or lung transplantation and their organ donors. * written consent from the recipients exclusion criteria: * lack of consent * non-evaluable patient due to insufficient clinical information

Keywords: transplantation endocrine
central post-stroke pain - a prospective study

Conditions: Pain

Summary: part 1: the purpose of the first part of the study is to investigate the prevalence of pain at stroke onset and 3 and 6 months after stroke in a consecutive cohort of stroke patients admitted to a stroke unit. part 2: the purpose of the second part of the study is to identify patients who develop central post-stroke pain within the first 6 months following stroke and to try to identify early prognostic factors for the development of pain.

part 1: * within 3 days of admission: medical history, pain history, sensory examination * telephone follow-up at 3 and 6 months post-stroke: pain history part 2: * medical history, pain history, sensory examination

Eligibility criteria:
inclusion criteria: * recent cerebrovascular stroke exclusion criteria: * severe dementia, aphasia or psychosis * patients who cannot cooperate at time of inclusion * patients who do not understand danish

Keywords: central post-stroke pain post-stroke pain shoulder pain
educational program through video conference for inhaled therapies in cystic fibrosis patients

Conditions: Cystic Fibrosis

Summary: educational programs are essential for cystic fibrosis patients who need to take several different drugs every day. compliance is often klow in these patients, and clinicals and paramedics try to increase it, through educational programs. as for inhaled therapies, the cf center of montpellier uses a video conference tool to educate patients. the program may involve either the physiotherapist or the doctor or both. through the present study, the investigators would like to evaluate the current practice at the cf center of montpellier and verify if patients feel that the physiotherapist could handle the program on his own, without the support of a physician.


Eligibility criteria:
inclusion criteria: * cf patients * patient regularly assessed at the cf center of montpellier * major patients * patients who recently enrolled a video conference educational program or who will soon be part of it exclusion criteria: * patients not able to participate to a video conference educational program, due to lack of tools at their home

Keywords: inhaled therapy physiotherapist educational program
number of multiple breath washout tests in adults with pulmonary disease and healthy controls

Conditions: Healthy Controls; Chronic Obstructive Pulmonary Disease; Bronchial Asthma; Sarcoidosis

Summary: the investigators aim to determine the optimal number of measurements required for multiple-breath-washout derived lung function parameters in adults with pulmonary disease as well as in healthy controls


Eligibility criteria:
inclusion criteria: - informed consent exclusion criteria: * inability to perform multiple breath washout testing
use of robotics for cholecystectomy; retrospective review of outcomes, set up and learning curves

Conditions: Cholecystitis; Cholelithiasis

Summary: comparing the use of surgical robotics during a cholecystectomy, comparing different platforms and approaches (multi port verses single port).

this study is a restrospective review of charts, including operating room notes as well as operating room documentation of procedures. currently there are numerous methods considered to be the standard of care in the surgical treatment of cholecystitis, or cholelithiasis, including open surgery, laparoscopic, and robotic assisted laparoscopic surgery. this study retrospectively reviews the intraoperative and post operative clinical outcomes of laparoscopic and robotic assisted surgery at u.c. davis medical center to: 1) establish the role of robotics in laparoscopic surgery, and 2) to assess the learning curve by surgeons.

Eligibility criteria:
inclusion criteria: * patients that have undergone robotic assisted laparoscopic cholecystectomy exclusion criteria: * patients under the age of 18, or not choosing to have surgery.

Keywords: cholecystitis cholelithiasis
study of chemokine coreceptor 5 (ccr5) antagonist gw873140 in r5-tropic treatment-experienced hiv-infected subjects

Conditions: Infection, Human Immunodeficiency Virus I

Summary: the purpose of this study is to evaluate the safety and efficacy of the ccr5 antagonist gw873140 or placebo in combination with an optimized background regimen in treatment-experienced hiv-infected subjects with r5-tropic virus


Eligibility criteria:
inclusion criteria: * hiv-infected. * screening viral load at least 5000copies/ml. * r5-tropic only virus at screening. * total prior antiretroviral experience of at least 3 months and documented resistance to at least one drug in each of the following classes: nucleoside reverse transcriptase inhibitors (nrti), non-nucleoside reverse transcriptase inhibitors (nnrti), and protease inhibitors (pi). * stable antiretroviral regimen (or no antiretroviral treatment) for at least 4 weeks before screening. * able to receive a ritonavir-boosted protease inhibitor during treatment studies. * women of childbearing potential must use specific forms of contraception. exclusion criteria: * acute laboratory abnormalities. * history of pancreatitis or hepatitis, hepatitis b or hepatitis c coinfection, or any chronic liver disease. screening liver function tests will be used to determine eligibility. * r5/x4-tropic, x4-tropic only, or non-phenotypeable virus at screening. * changes to antiretroviral therapy from 4 weeks prior to screening until day 1 of treatment study. * pregnancy or breastfeeding women. * recent participation in an experimental drug trial. * prior use of a ccr5 or cxcr4 antagonist. * significant ecg abnormalities or significant history of active pancreatitis, hepatitis, opportunistic infections, malabsorption disorders, cancer, or severe illness. * current use of certain medications may exclude participation in this study. * additional qualifying criteria and laboratory test requirements to be assessed by study physician.

Keywords: hiv-1 gw873140 ccr5 antagonist experienced
evaluation of the applicability of the cdeis to data obtained by the colonic capsule endoscopy in crohn disease

Conditions: Crohn Disease

Summary: the crohn's disease endoscopic index of severity is a validated index to assess the severity of ileocolonic lesions. depth of ulcerations are evaluated in each segment of ileocolon and the surface of lesions and ulcerations are reported on a 10-cm analogic scale. the crohn's disease endoscopic index of severity is the main score used in controlled trials to assess the endoscopic severity of lesions in crohn's disease. the investigators aim to conduct a prospective pilot study primarily to evaluate the applicability of the crohn's disease endoscopic index of severity to data obtained by the colonic capsule endoscopy procedure, provided that conventional ileo-colonoscopy and capsule endoscopy lead to comparable overall severity evaluations. secondary objectives are to assess reproducibility of the reading of data obtained by cce and to compare these data with those obtained by conventional ileocolonoscopy. if overall severity evaluations derived from the two examinations are not comparable, the secondary objectives will be used in an attempt to understand the reasons of this discrepancy.

twenty-four patients with cd will be included in the study on the basis of the need for an ileo-colonoscopy whatever the indication. * males and females patients more than 18-years-old * known colonic cd patients with a diagnosis based on established clinical, endoscopic, ra-diologic, and histologic criteria * ileocolonoscopy scheduled * patients' agreement for the cce procedure to be performed within the week following the ileocolonoscopy. * previous imaging of small bowel (one or more) by small bowel follow through (sbft), magnetic resonance enteroclysis (mre) or computed tomography enterography (cte) performed in the last 12 months

Eligibility criteria:
inclusion criteria: * males and females patients more than 18-years-old * known colonic cd patients with a diagnosis based on established clinical, endoscopic, ra-diologic, and histologic criteria * ileocolonoscopy scheduled * patients' agreement for the cce procedure to be performed within the week following the ileocolonoscopy exclusion criteria: * surgery of one or more segment of the colon or terminal ileum * non colonic cd * high risk for capsule retention defined by the presence of clinically significant obstructive symptom related to intestinal or colonic stricture detected by small bowel imaging * stenosis of the colon or ileum not passed by the colonoscope * treatment with antitnf or biotherapy after the ileocolonoscopy and before the cce procedure

Keywords: crohn disease crohn's disease endoscopy index of severity colon capsule endoscopy crohn's disease located in colon and/or ileum